[1] |
HARDING E. WHO global progress report on tuberculosis elimination[J]. Lancet Respir Med, 2020, 8(1):19.
DOI
PMID
|
[2] |
CHAKAYA J, KHAN M, NTOUMI F, et al. Global tuberculosis report 2020-reflections on the global TB burden,treatment and prevention efforts[J]. Int J Infect Dis, 2021, 113(Suppl 1):S7-S12.
DOI
URL
|
[3] |
KANG W L, WANG G R, WU M Y, et al. Interferon-gamma release assay is not appropriate for the diagnosis of active tuberculosis in high-burden tuberculosis settings:a retrospective multicenter investigation[J]. Chin Med J(Engl), 2018, 131(3):268-275.
|
[4] |
SIA J K, RENGARAJAN J. Immunology of Mycobacterium tuberculosis infections[J]. MicrobiolSpectr, 2019, 7(4):10.
|
[5] |
结核病分类(WS196—2017)[J]. 新发传染病电子杂志, 2018, 3(3):191-192.
|
[6] |
COMELLA-DEL-BARRIO P, DE SOUZA-GALVÃO M L, PRAT-AYMERICH C, et al. Impact of COVID-19 on tuberculosis control[J]. Arch Bronconeumol, 2021, 57:5-6.
|
[7] |
World Health Organization. Global tuberculosis report 2020[EB/OL]. (2020-10-15)[2020-10-30]. .
|
[8] |
LIU Y H, CHEN S, GAO J T, et al. The China tuberculosis clinical trials consortium network:a model for international TB clinical trials capacity building[J]. Infect Dis Poverty, 2020, 9(1):52.
DOI
|
[9] |
RUAN Q, ZHANG S, AI J, et al. Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients:a systemic review and meta-analysis[J]. Clin Rheumatol, 2016, 35(2):417-425.
DOI
URL
|
[10] |
BEGLINGER C, DUDLER J, MOTTET C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy[J]. Swiss Med Wkly, 2007, 137(43-44):620-622.
DOI
PMID
|
[11] |
PERSON A K, PETTIT A C, STERLING T R. Diagnosis and treatment of latent tuberculosis infection:an update[J]. Curr Respir Care Rep, 2013, 2(4):199-207.
DOI
URL
|
[12] |
SANTOS J A, DUARTE R, NUNES C. Host factors associated to false negative and indeterminate results in an interferon-γ release assay in patients with active tuberculosis[J]. Pulmonology, 2020, 26(6):353-362.
DOI
PMID
|
[13] |
王新宁, 施旭东. 化学发光法结核分枝杆菌特异性细胞免疫反应检测在肺结核辅助诊断中的价值[C]. 中华医学会结核病学分会2019年全国结核病学术大会论文汇编, 2019:439.
|
[14] |
AI L, FENG P, CHEN D, et al. Clinical value of interferon-γ release assay in the diagnosis of active tuberculosis[J]. Exp Ther Med, 2019, 18(2):1253-1257.
DOI
PMID
|
[15] |
孙丹雄. γ-干扰素释放试验假阴性影响因素研究进展[J]. 国际呼吸杂志, 2020, 40(22):1756-1760.
|
[16] |
陈诚, 杨健, 高海燕, 等. γ-干扰素释放试验结果的评价与定量界值的探索[J]. 国际呼吸杂志, 2018, 38(17):1299-1305.
|
[17] |
马进宝, 马婷婷, 任斐, 等. 涂阳肺结核患者γ-干扰素释放试验假阴性的影响因素分析[J]. 中国防痨杂志, 2020, 42(12):1299-1304.
|
[18] |
LV D, LIU Y, GUO F, et al. Combining interferon-γ release assays with lymphocyte enumeration for diagnosis of Mycobacterium tuberculosis infection[J]. J Int Med Res, 2020, 48(6):300060520925660.
|